Mapi Completes the Acquisition of Select Life Sciences Services

Mapi, a leading Health Research and Commercialization services company, has completed the acquisition of select Optum Life Sciences services, including North American and European Regulatory Consulting, Late Phase CRO and European Health Economics and Outcomes Research (HEOR) teams.

“Today’s therapeutics market is driven by patient outcomes and treatment value proven by real-world evidence. This acquisition enables Mapi to strengthen our industry-leading expertise and integrated solutions to help our clients accelerate market adoption of their novel therapeutics,” said James Karis, Mapi’s Chief Executive Officer. “Mapi is an industry leader in Patient Reported Outcomes research and delivers global proficiency in Health Economics, unparalleled depth of experience in Health Research and global expertise in the commercialization of novel therapeutics. With this acquisition, we are also the largest independent company exclusively dedicated to Health Research and Commercialization services.”